Microbiome alterations in Alzheimer's disease: A systematic review of current evidence and global perspectives

Background Growing evidence implicates the gut–brain axis in Alzheimer's disease (AD), with gut microbiome dysbiosis proposed to modulate neuroinflammation, amyloid pathology, and cognitive decline. Objective To systematically synthesize human studies (2021–2025) profiling gut microbiomes in AD; identify consistent taxonomic and functional signatures; map geographic study distribution; and highlight translational gaps. Methods A PRISMA-compliant systematic review of human studies using 16S rRNA, metagenomics, metatranscriptomics, or fecal microbiota transplantation (FMT)/probiotic designs was conducted. Two reviewers screened studies and assessed quality using Joanna Briggs Institute tools. Owing to heterogeneity, findings were narratively synthesized across microbiome diversity, taxonomy, function, metabolism, oral–brain links, causality, interventions, and predictive analyses. Results Thirty-seven studies, mainly from Asia with some from Europe, North America, and Africa, revealed consistent gut dysbiosis in AD. Findings show reduced alpha-diversity, loss of short-chain fatty acid-producing bacteria (e.g., Faecalibacterium prausnitzii , Bifidobacterium ), and enrichment of pro-inflammatory taxa ( Escherichia/Shigella , Proteobacteria ). Functional analyses indicate reduced butyrate synthesis, disrupted lipid and tryptophan–kynurenine metabolism, and links with apolipoprotein epsilon (ε4) gene and cognition. Limited causal evidence arises from Mendelian randomization and small FMT trials, with randomized, longitudinal confirmation still needed. Conclusions Current evidence suggests a biologically plausible association between gut microbiota and AD pathogenesis, positioning microbiome-derived biomarkers and interventions as promising but still exploratory avenues. Harmonized, longitudinal, multi-omic, and geographically inclusive studies are urgently needed to clarify causal mechanisms and translate these correlational findings into validated diagnostics and therapeutics.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease Reports
Published
2026-03-01
DOI
https://doi.org/10.1177/25424823261436287
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbiome alterations in Alzheimer's disease: A systematic review of current evidence and global perspectives

Chioma Ogochukwu Anorue, Olalekan John Okesanya, Jerico Bautista Ogaya, OA Talabi et al.
Journal of Alzheimer s Disease Reports
Gut microbiota and health
article

Microbiome alterations in Alzheimer's disease: A systematic review of current evidence and global perspectives

Chioma Ogochukwu Anorue, Olalekan John Okesanya, Jerico Bautista Ogaya, OA Talabi, Pelumi Daniel Adewole, Khalifat Boluwatife Obadeyi, Uthman Okikiola Adebayo, Tolutope Adebimpe Oso, Mohamed Mustaf Ahmed, Don Eliseo Lucero-Prisno, Oluwatobi Babajide Ayelaagbe
article en

Abstract

Background Growing evidence implicates the gut–brain axis in Alzheimer's disease (AD), with gut microbiome dysbiosis proposed to modulate neuroinflammation, amyloid pathology, and cognitive decline. Objective To systematically synthesize human studies (2021–2025) profiling gut microbiomes in AD; identify consistent taxonomic and functional signatures; map geographic study distribution; and highlight translational gaps. Methods A PRISMA-compliant systematic review of human studies using 16S rRNA, metagenomics, metatranscriptomics, or fecal microbiota transplantation (FMT)/probiotic designs was conducted. Two reviewers screened studies and assessed quality using Joanna Briggs Institute tools. Owing to heterogeneity, findings were narratively synthesized across microbiome diversity, taxonomy, function, metabolism, oral–brain links, causality, interventions, and predictive analyses. Results Thirty-seven studies, mainly from Asia with some from Europe, North America, and Africa, revealed consistent gut dysbiosis in AD. Findings show reduced alpha-diversity, loss of short-chain fatty acid-producing bacteria (e.g., Faecalibacterium prausnitzii , Bifidobacterium ), and enrichment of pro-inflammatory taxa ( Escherichia/Shigella , Proteobacteria ). Functional analyses indicate reduced butyrate synthesis, disrupted lipid and tryptophan–kynurenine metabolism, and links with apolipoprotein epsilon (ε4) gene and cognition. Limited causal evidence arises from Mendelian randomization and small FMT trials, with randomized, longitudinal confirmation still needed. Conclusions Current evidence suggests a biologically plausible association between gut microbiota and AD pathogenesis, positioning microbiome-derived biomarkers and interventions as promising but still exploratory avenues. Harmonized, longitudinal, multi-omic, and geographically inclusive studies are urgently needed to clarify causal mechanisms and translate these correlational findings into validated diagnostics and therapeutics.

Journal of Alzheimer s Disease ReportsVol. 10
University of Thessaly (GR), University of Lagos (NG), Bowen University (NG), University College Hospital, Ibadan (NG), Palompon Institute of Technology (PH), University of Makati (PH), McPherson University (NG), London School of Hygiene & Tropical Medicine (GB), Faculty of Public Health (GB), SIMAD University (SO), Federal Medical Centre (NG), Alex Ekwueme Federal University, Ndufu-Alike
Openalex Percentile: Top 9%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.